Skip to main content

Table 1 Epidemiological characteristics of the 4 included articles that presented longitudinal data

From: Leprosy detection rate in patients under immunosuppression for the treatment of dermatological, rheumatological, and gastroenterological diseases: a systematic review of the literature and meta-analysis

Author

Autoimmune disease

Medications

Cases

(n)

Population

(n)

Screening time (years)

Period detection rate/100,000

Detection rate/100,000/year

Lopes 2015 [35]

Juvenile Lupus Erythematosus

Prednisone, Hydroxychloroquine, Mycophenolate mofetil, Cyclophosphamide

1

312

32

320.50

10.02

Burmester 2016 [36]

Rheumatoid Arthritis

Tocilizumab

1

1262

2

79.20

39.62

Titton 2011 [23]

Rheumatic Diseases;

Anti-TNF and DMARDs

1

1037

0.83

96.43

116.18

Wallis RS 2005 [31]

Not clear

Infliximab

1

197,000

4

0.51

0.13

Total*

4

199,611

2.00

  1. n Number of patients, DMARDs Disease-modifying antirheumatic drugs, * Unadjusted values